Neumora Therapeutics, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Joshua Pinto appointed CEO and board member; Paul Berns becomes Executive Chair. Company reports $116.8M cash (supporting operations into Q3 2027), Q2 2026 net loss of $43.1M (vs. $52.7M prior year), and R&D expense of $29.3M (vs. $38.7M prior year). Pipeline: NMRA-215 IND submission planned Q4 2026; NMRA-511 Phase 2 data expected Q4 2026; NMRA-898 Phase 1 data expected H2 2026.
Why this rating
Leadership change is positive signal but not transformational at clinical stage. Cash runway ~15 months is adequate but not exceptional. Improving burn rate is constructive; pipeline remains early-stage clinical with execution risk.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.